Navigation Links
NIH Funds Synedgen to Develop a New Drug to Improve Airway Clearance
Date:9/27/2013

Claremont, CA (PRWEB) September 27, 2013

Synedgen announces the award of a National Heart Lung and Blood Institute (NHLBI) Small Business Innovation Research grant from the NIH to explore the mechanisms of a natural modified biopolymer to both reduce the viscosity of mucus and the cohesion of biofilms, potentially leading to a pulmonary treatment for patients with cystic fibrosis (CF) to enhance airway clearance and augment the activity of standard therapeutic antibiotics. In preliminary studies, this new approach to controlling molecular interactions in thick sputum and biofilms has shown significant reductions in viscosity and cohesion.

Due to a genetic defect, CF patients have thicker mucus in their lungs and respiratory tract that is very difficult to clear. The resulting accumulation of mucus allows for colonization by biofilm-producing bacteria. The combination of thick mucus and invasive bacterial biofilms can dramatically reduce lung function of CF patients. Because the biofilms provide a sheltered environment to protect bacteria from antibiotic treatments, CF patients typically suffer from persistent and recurrent lung infections.

In partnership with Dr. Steven Rowe, Associate Professor School of Medicine, University of Alabama Birmingham (UAB), and Director of the CFF Therapeutics Development Network’s Center for CFTR Detection, researchers will be assessing a new drug’s role in reducing the viscosity of patient derived sputum. Using human bronchial cell lines that have the CF defect, they will study the drug’s effect on the relationship of sputum viscosity and mucociliary clearance by assessing activity on monolayers of ciliated cells. Since the drug has already been shown to disrupt biofilms, studies to examine the combined effect of the drug with standard antibiotic treatments will explore the effects of this new drug in enhancing the antibiotic therapies used in CF patients.

“Our approach is to tackle biofilms and sputum, reducing their cohesion and viscosity to allow the patient to clear them both. Our preliminary data demonstrates that our polymeric drug both reduces the viscosity of CF sputum and improves sputum mobility in vitro, and separately loosens biofilms,” stated Synedgen President Shenda Baker. “We hypothesize the drug will have significant synergistic activity with traditional antibiotics, and are eager to explore the magnitude and duration of these effects in mucus, biofilms, and in combination.”

In other studies of pathogenic infection and mucosal surface damage, this new drug has been shown to reduce inflammation at the surface. Since cystic fibrosis is a disease severely affected by airway inflammation, future studies will also examine the drug’s potential additional role in mitigating pulmonary inflammation.

“The preliminary data are extremely exciting,” stated Dr. Steven Rowe, “and could provide a new avenue to address mucus stasis in CF lung disease, potentially improving lung health.”

Preliminary results from these studies will be presented in October at the 27th Annual North American Cystic Fibrosis Conference. Synedgen hopes its new drug will make the sputum flow more freely, break up pathogenic biofilms and also enhance activity of standard antibiotics, providing a new and highly effective pulmonary treatment to help CF patients breathe more easily and combat lung infections.

Research reported in this press release was supported by the National Heart Lung and Blood Institute of the National Institutes of Health under award number 1R43HL118867. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Synedgen
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces. Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11167611.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
2. QB3-Industry Biotech Startup Partnership Funds Two Projects
3. German Academic Exchange Service funds international project on spintronics
4. NSBRI Funds Cerebrotech to Accelerate Development of Brain Monitoring Device
5. Express Diagnostics to Raise Funds for American Cancer Society During Blue Earth’s Giant Days Parade
6. Kitware Receives Funds from U.S. Air Force Research Lab to Extend the Bender Toolkit for Anatomical Model Repositioning
7. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
8. Synedgen Announces Issuance of Patent to Optimize Animal Health
9. Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
10. Scarred for Life? Synedgen Hopes Not
11. Synedgen's Synoplex® is Headed to the Lewa Wildlife Conservancy in Kenya
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):